Research paper

Prosaposin promotes the proliferation and tumorigenesis of glioma through toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway

Yang Jiang a,1, Jinpeng Zhou a,1, Peng Luo a, Huiling Gao b, Yanju Ma c, Yin-Sheng Chen d, Long Li a, Dan Zou e, Ye Zhang c,*, Zhitao Jing a,***

a Department of Neurosurgery, The First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang City 110001, China
b Department of Medical Oncology, Cancer Hospital of China Medical University, Shenyang 110042, China
c Department of Neurosurgery/Neuro-oncology, SunYat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
d Department of Medical Oncology, Cancer Hospital of China Medical University, Shenyang 110042, China
e Z. He’s World of Oncology, The First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang City 110001, China

ARTICLE INFO

Article history:
Received 26 June 2018
Received in revised form 17 October 2018
Accepted 22 October 2018
Available online 29 October 2018

Keywords:
Glioma
Glioma stem cells
Prosaposin
Proliferation
Tumorigenesis

ABSTRACT

Background: As a neurotrophic factor, prosaposin (PSAP) can exert neuroprotective and neurotrophic effects. It is involved in the occurrence and development of prostate and breast cancer. However, there is no research about the role of PSAP in glioma.

Methods: The PSAP overexpressed or silenced glioma cells or glioma stem cells were established based on Lentiviral vector transfection. Cell viability assay, Edu assay, neurosphere formation assay and xenograft experiments were used to detect the proliferative ability. Western blot, Elisa and luciferase reporter assays were used to detect the possible mechanism.

Findings: Our study firstly found that PSAP was highly expressed and secreted in clinical glioma specimens, glioma stem cells, and glioma cell lines. It was associated with poor prognosis. We found that PSAP significantly promoted the proliferation of glioma stem cells and cell lines. Moreover, PSAP promoted tumorigenesis in subcutaneous and orthotopic models of this disease. Furthermore, GSEA and KEGG analysis predicted that PSAP acts through the TLR4 and NF-κB signaling pathways, which was confirmed by western blot, immunoprecipitation, immunofluorescence, and use of the TLR4-specific inhibitor TAK-242.

Interpretation: The findings of this study suggest that PSAP can promote glioma cell proliferation via the TLR4/NF-κB signaling pathway and may be an important target for glioma treatment.

Fund: This work was funded by National Natural Science Foundation of China (Nos. 81101917, 81270036, 81201802, 81673025), Program for LiaoNing Excellent Talents in University (No. LR2014023), and LiaoNing Province Natural Science Foundation (Nos. 20170541022, 20172250290). The funders did not play a role in manuscript design, data collection, data analysis, interpretation nor writing of the manuscript.

© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Glioma is the most common primary malignant tumor of the central nervous system. Current treatment approaches (i.e., surgery, radiotherapy, and chemotherapy) are not ideal, and the average survival time of patients is <15 months [1]. Recent studies have shown that gliomas can promote their own growth, angiogenesis, and invasion by the release of a series of autocrine or paracrine secretory proteins (e.g., growth factors and cytokines), which can also contribute to treatment tolerance [2,3]. For example, glioma can promote its proliferation and tumorigenesis by secreting the Wnt secretion protein Evi/Gpr177 [4]. Glioma also promotes mesenchymal transition and invasion by the secretion of TGF-β [5]. Therefore, the regulation and intervention of glioma-related secretory proteins may be an important target for the treatment of this disease [6,7].

Prosaposin (PSAP) is a conserved glycoprotein with multiple functions, including a role in the metabolism of sphingomyelin and...
Research in context

Evidence before this study

Glioma is the most common primary malignant tumor of the central nervous system. Current treatment approaches (i.e., surgery, radiotherapy, and chemotherapy) are not ideal, and the average survival time of patients is <15 months. The regulation and intervention of glioma-related secretory proteins may be an important target for the treatment of this disease. A conserved glycoprotein, Prosaposin (PSAP) can act as a neurotrophic factor and participate in the metabolism of sphingomyelin and ceramide. Overexpression and secretion of PSAP are correlated with tumorigenesis in prostate and breast cancer. Furthermore, PSAP can cause tolerance to endocrine therapy in breast cancer via androgen receptor activation. In addition, PSAP is highly expressed in gallbladder cancer and is expected to become a biomarker of that disease. However, as neurotrophic factor, the role of PSAP in glioma is still not completely clear.

Added value of this study

Our study found abnormally high PSAP expression levels in glioma through bioinformatics analysis and confirmed that PSAP could promote the growth of glioma. KEGG and GSEA analysis also revealed that PSAP is involved in the TLR4 signaling pathway. Because TLR4 is stimulated by different ligands, it has multiple regulatory roles in glioma. This study suggests that overexpression of PSAP promotes glioma growth and tumorigenesis through activation of the TLR4/NF-κB signaling pathway. PSAP may be an possible target in glioma treatment.

Implications of all the available evidence

We confirmed that PSAP is overexpressed in glioma, and can bind to TLR4 to activate the NF-κB signaling pathway, which may induce the synthesis and secretion of inflammatory factors and promote the growth of glioma stem cells and tumor cells. PSAP may be an important target for inhibiting glioma growth and improving glioma prognosis.

Our study found abnormally high PSAP expression levels in glioma through bioinformatics analysis and confirmed that PSAP could promote the growth of glioma. KEGG and GSEA analysis also revealed that PSAP is involved in the TLR4 signaling pathway. Toll-like receptors (TLRs) belong to a class of pattern recognition receptors (PRRs), which can identify pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [28,29]. Because TLR4 is stimulated by different ligands, it has multiple regulatory roles in glioma [28,30]. This study suggests that overexpression of PSAP promotes glioma growth and tumorigenesis through activation of the TLR4/NF-κB signaling pathway.

2. Materials and methods

2.1. Cell culture and cell treatment

The human glioma cell line T98G was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). U87 and U251 cells were purchased from the Chinese Academy of Sciences cell bank (Shanghai, China). HA, LN229, and SNB19 cells were a gift from Professor Tao Jiang, Department of Molecular Neuropathology, Beijing Neurosurgical Institute. H4 and A172 cells were purchased from iCell Bioscience Inc. (Shanghai, China). All cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM, HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Gibco) at 37 °C with 5% CO2.

2.2. Patients and samples

Seventy clinical samples from glioma patients and ten control samples from brain injury patients were collected from the First Affiliated Hospital of China Medical University from January 2007 to December 2011. According to the World Health Organization (WHO) classification guidelines, there were 20 cases of WHO grade II, 25 cases of WHO grade III, and 25 cases of WHO grade IV. Two neuropathologists verified the histological diagnosis of each sample. This study was approved by the ethics committee of the First Affiliated Hospital of China Medical University and written informed consent was obtained from each patient.

2.3. Lentiviral vector construction and transfection

siRNA TLR4 were generated by Gene-Chem (Shanghai, China). Two siRNA sequences were designed for PSAP silencing: forward 5′-CCGAAAUAGUCUGCGUCUATT-3′, reverse 5′-AUGAAAGCAGACAGUGU CUGTT-3′ and forward 5′-CCACGAAAUGUCGUGUATT-3′, reverse 5′-AACACUGACACUUUGCGGTT-3′. The siRNA sequences for TLR4 silencing were: forward 5′-CGAAGAUUACUGACUAAUU-3′, reverse 5′-UAAGUCAUAAACUAUGACG-3′. Puromycin (Sigma, Santa Clara, CA, USA) selection was performed on the transfected cells at a concentration of 10 μg/ml for 15 days. qPCR and western blotting were used to determine the effectiveness of silencing and overexpression.
2.4. Real-time PCR

Real-time PCR was performed as previously described [31]. Total RNA was isolated from glioma cells using the Mini-BEST Universal RNA Extraction kit (TaKaRa, Kyoto, Japan) according to the manufacturer’s instructions. First-strand cDNA was synthesized using Prime-Script RT Master Mix (TaKaRa), SYBR Green Master Mix (TaKaRa) was used for qPCR detection (PCR LightCycler480, Roche Diagnostics Ltd., Basel, Switzerland). The sequences of the PCR primer pairs are as follows: PSAP, forward 5′-CCGGTTCTGGACTGAAAG-3′ and reverse 5′-TATG TCCGAGGAAGGATTG-3′; β-actin, forward 5′-CATGACCTTGTACATC CAGGC-3′ and reverse 5′-CTCCTTAATGTACCGACGAT-3′.

2.5. Western blotting and immunoprecipitation

Western blotting was performed as previously described [31]. Cell protein was isolated from cells using a cell protein extraction kit (KeyGen Biotechology, Nanjing, China). Trichloroacetic acid (TCA) protein precipitation was used to collect the secretory protein in the cell supernatants [32]. The total protein included the protein from both the cells and supernatants and was used for western blotting and immunoprecipitation. An equivalent amount of protein from each sample was separated by 4 to 20% SDS-PAGE (Genscript, Nanjing, China) and transferred to a nitrocellulose membrane. The membranes were blocked with 2% bovine serum albumin (KeyGen Biotechology) and incubated with primary antibody at 4 °C overnight. The membranes were washed with TBST and then incubated with secondary antibody. The Chemiluminescence ECL kit (Beyotime Biotechnology, Beijing, China) was used to detect the bands, which were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

For immunoprecipitation, cell pellets were lysed using RIPA lysis buffer containing proteasome inhibitor (Beyotime Biotechnology). Whole cell lysates were immunoprecipitated for 12 h at 4 °C with gentle shaking using a rabbit monoclonal antibody against PSAP or a mouse monoclonal antibody against TLR4 (Abcam) that was prebound to protein A-Sepharose 4B beads (GE Healthcare, Pittsburgh, PA, USA). Appropriate isotype antibodies were used as controls (Abcam). The beads were washed and boiled in SDS buffer, and the eluates were analyzed by western blotting.

2.6. Immunohistochemistry (IHC)

The IHC of tumor specimens was performed as previously described [31]. Paraffin-embedded sections were labeled with a primary antibody against PSAP (Abcam), and samples were imaged using a light microscope (Olympus, Tokyo, Japan). The immunohistochemical results were evaluated according to the German immunohistochemical score (GIS) [33,34].

2.7. Enzyme-linked immunosorbent (ELISA)

ELISA was performed as previously described [31]. The concentrations of PSAP, IL1β, IL6, IL8, IL10, IP-10, MCP1, RANTES, and IFN-β in the media supernatant of the glioma cell lines and stem cells were determined using commercially available ELISA kits (Cusabio, Stratech, Suffolk, UK). All the ELISA readings were normalized to the protein concentration in the control group.

2.8. Immunofluorescence

Immunofluorescence staining was performed as previously described [31]. Briefly, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, blocked with 5% BSA, and probed with primary antibody at 4 °C overnight. The samples were washed with PBS for 5 min and then stained with FITC- or rhodamine-conjugated secondary antibody. The cells were then counterstained with DAPI (Sigma). Staining was visualized using a laser scanning confocal microscope (Olympus).

2.9. Cell viability assay

Cell viability was determined using the CellTiter 96® AQueous Non-Radioactive cell proliferation assay kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, cells were cultured in 96-well plates at a density of 1 × 10^3 cells/well for 24, 48, 72, 96, or 120 h. After the incubation, MTS (20 μl) was added to each well for 3 h at 37 °C. The absorbance at 495 nm was detected using an ultraviolet spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA).

2.10. EdU assay

The 5-ethyl-20-deoxyuridine (EdU) incorporation assay was performed using an EdU assay kit (Beyotime Biotechnology) according to the manufacturer instructions. Briefly, cells were seeded into 24-well plates at a density of 1 × 10^3 cells per well for 24 h and then treated with 50 μM EdU for 2 h at 37 °C. The cells were then fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, incubated with 100 μl Click Additive Solution for 30 min, and stained with 100 μl DAPI. The images were taken with a laser scanning confocal microscope (Olympus). The percentage of EdU-positive cells was calculated.

2.11. Neurosphere formation assay

The neurosphere formation assay was performed as previously described [31]. Briefly, glioma stem cells were seeded in 24-well plates at a density of 200 cells per well and cultured in fresh medium for seven days. The relative neurosphere size and number of neurospheres were counted using a light microscope (Olympus).

2.12. Luciferase reporter assays

Luciferase reporter assays were performed as previously described [31]. Briefly, NF-KappaB and IRF3 reporter plasmids were constructed by Gene-Chem (Shanghai, China). Cells were seeded into 96-well plates at a density of 5 × 10^3 cells per well and transfected with different plasmids. After 48 h, the cells were lysed, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer’s instructions. Each experiment was independently repeated three times.

2.13. Xenograft experiments

Six-week-old female BALB/c nude mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and bred in laminar flow cabinets under specific pathogen-free conditions in the Laboratory Animal Center of China Medical University. All animal experiments were performed in accordance with the Animal Care Committee of China Medical University. Cells were injected orthotopically (5 × 10^4) into the mouse brain at 2 mm lateral and 2 mm anterior to the bregma using a stereotaxic apparatus as previously described [31]. Five mice in each group was observed daily for signs of distress or death and tumor growth. The tumor volume was calculated according to the formula: V = (D × d[2])/2, where D represents the longest diameter and d represents the shortest diameter.

2.14. Bioinformatics analysis

The data on mRNA expression and the clinical material from patients were obtained from the Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov) and the Chinese Glioma Genome Atlas (CGGA, http://www.cgga.org.cn). Gene set enrichment analysis (GSEA, http://www.broadinstitute.org/gsea/index.jsp) was used to detect sets of
genes from signaling pathways that showed statistically significant differences between higher and lower PSAP expression groups.

2.15. Statistical analysis

Statistical analysis was performed using SPSS 22.0 software. All experiments were repeated at least three times, and the results are presented as the mean ± the standard error of the mean (SEM). The chi-square test and t-test were used to evaluate the statistical significance between groups. Differences in survival rates were analyzed using the log-rank test and Kaplan–Meier analysis. All statistical tests were two-sided, and statistical significance was defined as a p-value <0.05.

3. Results

3.1. PSAP is highly expressed in gliomas and is associated with poor prognosis

We first evaluated the expression of PSAP in 70 glioma patients and 10 normal brain tissues. All results (i.e., qPCR, western blot, and immunohistochemistry) showed that the expression of PSAP in glioma was significantly higher than that in normal brain tissue. In addition, the expression was significantly increased with higher glioma WHO grades (Fig. 1 a, b, c, d and Supplementary Fig. 1). Furthermore, according to our clinical material, the last patient of the PSAP high expression population was lost to follow up at week 65, and the last patient of the PSAP low expression population died at week 80. Kaplan–Meier survival analysis demonstrated that the median survival time of patients with higher PSAP expression was 22 months compared to 29 months for patients with lower PSAP expression. Therefore, the survival time of glioma patients with higher PSAP expression was significantly shorter than that of the lower expression group (P = 0.034) (Fig. 1 e).

We isolated glioma stem cells (GSCs) from six patient gliomas representing different pathological diagnoses (e.g., WHO grade II, III, or IV). The six GSC populations were designated GSC-21 and GSC-22 (WHO grade II), GSC-31 and GSC-32 (WHO grade III), and GSC-41 and GSC-42 (WHO grade IV). All GSCs were confirmed by their ability to differentiate and immunofluorescence staining of the stem cell markers CD133 and nestin (Fig. 2 a, b). Western blot and qPCR showed that PSAP expression in the WHO grade IV GSCs (GSC-41 and GSC-42) was higher than that of the WHO grade II GSCs (GSC-21 and GSC-22) (Fig. 2 c, d). In addition, secretion of PSAP into the medium was significantly higher for the WHO grade IV GSCs than for the WHO grade II GSCs (Fig. 2 f). Furthermore, we evaluated the expression of PSAP in common glioma cell lines. Using western blot, qPCR, and ELISA, we found that the expression and secretion of PSAP in common glioma cell lines. All the tested glioma cell lines expressed higher levels of PSAP than the normal human astrocyte cell line HA. Moreover, U87, which is one of the most aggressive and malignant glioma cell lines, had the highest PSAP expression levels. In contrast, SNB19, an astrocytoma cell line that is less aggressive and malignant, expressed the lowest PSAP levels (Fig. 2 c, e). Based on these results,
there appears to be significantly higher expression and secretion of PSAP in glioma with a significant correlation between the expression of PSAP and poor patient prognosis.

3.2. PSAP regulates the growth of glioma cells

To determine the effect of PSAP on glioma tumor cell and stem cell growth, we designed two siRNA sequences with a lentivirus envelope to silence PSAP expression. We chose U87 and GSC-42 for lentiviral infection because they had the highest PSAP expression. We used western blot, qPCR, and ELISA to confirm the knockdown of PSAP expression. As shown in Fig. 3 a-c, the levels of PSAP expression and secretion were significantly decreased in both U87 and GSC-42 following transfection of PSAP siRNA. Furthermore, knockdown of PSAP expression significantly decreased the growth of U87 and GSC-42 as determined by the MTS and EdU assays (Fig. 3 d-f). PSAP siRNA infection of GSC-42 also reduced the rate of neurosphere formation and size of the neurospheres compared to the control group (Fig. 3 g).

To further evaluate the effect of PSAP on the growth of glioma tumor cells and stem cells, we overexpressed PSAP in SNB19 and GSC-21, which was confirmed by western blot, qPCR, and ELISA (Fig. 4 a, b, c). MTS and EdU assays confirmed that SNB19 and GSC-21 proliferation increased following PSAP overexpression (Fig. 4 d, e). Furthermore, the neurosphere formation rate and relative size of neurospheres formed by GSC-21 were significantly higher than the control group following PSAP overexpression (Fig. 4 f). These results confirm that PSAP plays a role in regulating glioma proliferation and a high level of PSAP synthesis and secretion can promote the growth of glioma cells.
3.3. PSAP increases glioma tumorigenesis

We further evaluated the effects of PSAP on tumorigenesis using orthotopic xenograft models. We followed the survival rates of nude mice after intracranial inoculation of GSC-42 cells with (PSAP-KD1, PSAP-KD2) or without (PSAP-NC) PSAP silencing. According to the Kaplan-Meier survival analysis, the median survival time (MST) of the GSC-42 PSAP-NC group was 35 days. Silencing of PSAP extended the MST to 56 and 52 days for the PSAP-KD1 and PSAP-KD2 groups, respectively (Fig. 5b). These data are consistent with the decreased intracranial tumor volume observed in the PSAP knockdown groups (Fig. 5a, b). Overexpression of PSAP in GSC-21 significantly decreased the MST of nude mice to only 23 days (MST, control group = 35 days), which was consistent with the larger tumor volumes observed in the PSAP overexpressing GSC-21 group compared to the control mice (Fig. 5a, c). These results clearly demonstrate that PSAP plays a role in glioma tumorigenesis.
3.4. PSAP regulates the NF-κB signaling pathway through the TLR4 signaling pathway

To explore the specific signaling pathways involved in PSAP mediated effects in glioma, we performed Gene Set Enrichment Analysis (GSEA) based on the TCGA and CGGA glioma databases and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis based on TCGA. We found that higher PSAP expression was associated with the TLR signaling pathway (Fig. 6a, b). Although Lrp1, a low-density lipoprotein, is one of the known receptors for PSAP, further analysis showed that there was the highest correlation between the expression of PSAP and TLR4 in the TCGA and CGGA glioma datasets compared to other TLRs or Lrp1 (Fig. 6c, d). Therefore, we selected the TLR signaling pathway as a possible pathway involved in PSAP regulation. Furthermore, the qPCR analysis demonstrated that there was a significant correlation between PSAP and TLR4 expression in the clinical glioma specimens (Fig. 6e).

Since PSAP is a secretory protein and TLR4 is a membrane protein, we investigated whether there was a direct association between these two proteins. CoIP was used to determine direct binding between
Fig. 5. PSAP regulates glioma tumorigenesis. a: Representative photographs show the intracranial tumor size in the coronal position. PSAP knockdown in GSC-42 decreased the intracranial tumor size whereas PSAP overexpression in GSC-21 increased the intracranial tumor size. n scale bar = 10 mm. b: Kaplan–Meier survival curves show that PSAP knockdown increased the survival time of GSC-42 tumor-bearing mice (n = 5). c: Kaplan–Meier survival curves show that PSAP overexpression in group reduced the survival time of GSC-21 tumor bearing mice (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001. (t-test).

Fig. 6. PSAP participates in the TLR4 signaling pathway. a: Gene set enrichment analysis (GSEA) indicates that high expression of PSAP is associated with the TLR signaling pathway in both the TCGA and CGGA databases. b: Kyoto Encyclopedia of Genes and Genome (KEGG) analysis suggests that PSAP participates in the TLR signaling pathway in TCGA database. c: TCGA analysis shows the correlations for TLRs/PSAP and Lrp1/PSAP. d: There is a positive correlation between PSAP and TLR4 in the TCGA and CGGA database (r = 0.5847, p < 0.0001 and r = 0.3638, p < 0.0001 respectively, Pearson correlation analysis). e: There is a positive correlation between PSAP and TLR4 in the clinical glioma specimens (r = 0.7342, p < 0.0001, Pearson correlation analysis).
PSAP and TLR4. Both TLR4 and PSAP were detected in the two CoIP assays (Fig. 7a). Furthermore, PSAP and TLR4 co-localized in the glioma cell membrane as determined by immunofluorescence, scale bar = 50 μm. c: PSAP modulation affects the expression and nuclear translocation of P65 in glioma cells as measured by immunofluorescence, scale bar = 50 μm. d: PSAP overexpression (d) and knockdown (e) regulated the secretion of pro-inflammatory cytokines in glioma cells as measured by ELISA. f, g: PSAP overexpression (f) or knockdown (g) alters the relative P65-mediated luciferase activity after TLR4 knockdown. All data are shown as the mean ± S.D. (3 experiments). *P, 0.05; **P, 0.01; ***P, 0.001. (t-test).

Fig. 7. PSAP regulates NF-κB signaling pathway via TLR4 activation in glioma. a: PSPA and TLR4 levels in GSC-42 cell lysates were measured by western blot following immunoprecipitation (IP) with PSAP (A) or TLR4 (B) antibodies. b: PSAP and TLR4 co-localize in the glioma cell membrane as demonstrated by immunofluorescence, scale bar = 50 μm. c: PSAP modulation affects the expression and nuclear translocation of P65 in glioma cells as measured by immunofluorescence, scale bar = 50 μm. d: PSAP overexpression (d) and knockdown (e) regulated the secretion of pro-inflammatory cytokines in glioma cells as measured by ELISA. f, g: PSAP overexpression (f) or knockdown (g) alters the relative P65-mediated luciferase activity after TLR4 knockdown. All data are shown as the mean ± S.D. (3 experiments). *P, 0.05; **P, 0.01; ***P, 0.001. (t-test).

PSAP and TLR4. Both TLR4 and PSAP were detected in the two CoIP assays (Fig. 7a). Furthermore, PSAP and TLR4 co-localized in the cell membrane of glioma cells as determined by immunofluorescence. This co-localization became more evident after PSAP overexpression in both SNB19 and GSC-42 cells and was significantly decreased in U87 and GSC-21 cells upon PSAP silencing (Fig. 7b). The binding of a ligand to TLR4 can result in TLR4 dimerization and recruitment of myeloid differentiation primary response gene 88 (MyD88) or Toll-interleukin receptor-domain-containing adapter-inducing interferon-β (TRIF) and other adapter proteins. Importantly, MyD88-mediated activation of the NF-κB signaling pathway can induce tumor inflammation and promote tumor development, and the MyD88-dependent pathway can contribute to glioma proliferation [28,35]. Therefore, NF-κB and IRF3 luciferase reporter assays were performed. Following TLR4 silencing, the relative P65-mediated luciferase activity was decreased in both the PSAP-overexpressing GSC-21 and PSAP-silenced GSC-42 cells, but there was no detectable change in IRF3-mediated luciferase activity (Fig. 7f, g). In addition, we used immunofluorescence to detect changes in P65 expression and location following PSAP regulation. We found that the expression and nuclear localization of P65 were weakened after PSAP silencing in U87 and GSC-42 but increased after PSAP overexpression in SNB19 and GSC-21 (Fig. 7c). Then we used western blotting to determine the relationship between PSAP and the main regulators of the NF-κB signaling pathway. We found that the expression of MyD88, p-P65, p-IκBα, p-IKKα/β and TBS1 were significantly downregulated after PSAP silencing in U87 and GSC-42 (Fig. 8a, b). Conversely, the
expression of these molecules was significantly upregulated following PSAP overexpression in SNB19 and GSC-21 (Fig. 8 c, d). Finally, ELISA was performed to measure the levels of secreted pro- and anti-inflammatory cytokines regulated by NF-κB or IFR3. The results showed that the secretion of the NF-κB-regulated cytokines (i.e., IL1β, IL6, IL8, IL10, IP-10, MCP1, and RANTES) were all decreased after PSAP knockdown and increased after PSAP overexpression. However, there was no change in IFN-β secretion, which is regulated by IRF3 (Fig. 7 d, e). These data suggest that PSAP can bind to TLR4 and activate MyD88-dependent signaling and the NF-κB signaling pathway.

3.5. Inhibition of TLR4 can block the proliferation and growth of glioma by PSAP

To further verify the role of TLR4 in promoting the proliferative effects of PSAP in glioma, we treated PSAP-overexpressing or empty vector control GSC-21 and SNB19 cells with a TLR4-specific inhibitor (TAK-242). TAK-242 can competitively bind to the TIR segment and block the activation of TLR4 induced by TIRAP and TRAM binding [36]. TAK-242 reduced the proliferation of PSAP overexpressing GSC-21 and SNB19 cells compared to the vehicle control group (Fig. 9 a, b, c). In addition, TAK-242 decreased the number and size of neurospheres from PSAP overexpressing GSC-21 cells compared to the vehicle control group (Fig. 9 d). The effect of TAK-242 treatment on the expression of TLR4 and the main regulators of the NF-κB signaling pathway was determined by western blotting. The results showed that the expression of myD88, p-P65, p-IκBα, and p-IKKα/β was decreased in PSAP overexpressing GSC-21 and SNB19 cells following TAK-242 treatment (Fig. 9 e). Therefore, the proliferative effects of PSAP on glioma are dependent on TLR4-mediated activation of the NF-κB signaling pathway.

4. Discussion

In addition to its role in prostate, breast, and gallbladder cancer [13,27,37,38], secretory PSAP may be involved in the development of glioma due to its neurotrophic effects [19,23]. By evaluating the expression and secretion of PSAP in clinical glioma specimens and cell lines using a panel of detection methods, we found that PSAP was expressed higher in glioblastoma and glioma compared to normal brain tissue [25,39]. Furthermore, Kaplan–Meier survival analysis revealed that the median survival time of patients with higher PSAP expression was significantly shorter than that of patients with lower PSAP expression. These data suggest that PSAP may play an important role in the development of glioma.

To demonstrate the growth-promoting effects of PSAP in gliomas, especially glioma stem cells, we used patient-derived glioma stem cells and glioma tumor cell lines to determine the effect of PSAP modulation on glioma proliferation. We found that PSAP overexpression promoted tumor growth whereas PSAP silencing inhibited growth. Orthotopic xenograft studies confirmed the effects of PSAP modulation on glioma cell growth and tumorigenesis. However, the survival times of mice injected with GSC-21 and GSC-42 are similar while the tumors formed by GSC-42 are almost 2.5 times larger than GSC-21. Since we didn’t perform the xenograft experiment of GSC-42 and GSC-21 simultaneously, there would be several factors affecting the survival time of nude mice beside the tumor volume, such as the resistant capacity of nude mice to the injected glioma and the different living environment. What’s more, the differences of proliferative and invasive capacities of glioma stem cells may play a key role in survival times.

There have been several published reports that found that PSAP could stimulate the production of thrombospondin-1 (TSP-1) in the tumor microenvironment of breast, prostate, lung, and ovarian cancer [40,41]. Because TSP-1 can inhibit angiogenesis and induce tumor cell apoptosis via the cell surface receptor CD36, PSAP functions as a tumor suppressor protein in those cancer settings [42]. Our experiments demonstrated that in glioma, TSP-1 expression did not noticeably change after PSAP overexpression or knockdown. Therefore, our results suggest that PSAP is truly involved in promoting glioma proliferation and growth without stimulating TSP-1 production.

To explore the exact mechanism of the PSAP proliferative effects in glioma, we performed GSEA and KEGG analysis based on the TCGA and CGGA glioma databases. The results suggested that higher PSAP
expression may be involved in the regulation of the Toll-like receptor signaling pathway. Further analysis revealed that there was a significant positive correlation between PSAP and TLR4 in multiple glioma databases and our clinical glioma specimens. Because PSAP is a secretory protein and TLR4 is a typical receptor protein, we hypothesized that PSAP bound to TLR4. Amazingly, immunofluorescence staining showed co-localization of PSAP and TLR4, and CoIP experiments confirmed that PSAP could bind to TLR4.

As a pattern recognition receptor, TLR4 can identify pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide, and damage-associated molecular patterns (DAMPs) [30,43,44]. The activation of TLR4 can lead to its dimerization, activation of the MyD88-dependent or -independent NF-κB signaling pathway, participation in the regulation of the tumor immune response, inflammatory response, and promotion of tumor growth, invasion, and other functions [45,46]. Possibly due to the ineffective of TLR4 knocking down, there have no discernible effect on NF-κB activity in both GSC-21 and GSC-42 cells expressing endogenous levels of PSAP. However, after PSAP overexpression or silence in TLR4 knocking down GSC-21 or GSC-42, the dependent effect of TLR4 became obviously and the luciferase reporter assays showed that PSAP binding to TLR4 could lead to the activation of MyD88-dependent NF-κB, and not MyD88-independent IRF3. Western blotting also showed PSAP overexpression could significantly increase the expression levels of MyD88, p-P65, p-IκBα, and p-IKKα/β, and the nuclear translocation of P65. The opposite results were obtained after PSAP silencing. These results are further supported by the finding that PSAP overexpression induced the expression of cytokines and inflammatory factors that are mainly regulated by the NF-κB signaling pathway (IL1β, IL6, IL8, IL10, IP10, MCP-1, and RNATES). Furthermore, recent studies have shown that inflammation, especially the secretion of many cytokines and chemokines in the tumor microenvironment, plays an important role in the occurrence, development, and prognosis of glioma [47–50]. For example, IL-1β expression can promote the proliferation of glioma cells through the ERK and JNK signaling pathways [51,52]. IL-6 can promote the proliferation of glioma cells through the JAK2/STAT3 signaling pathway [31,53]. IL-8 participates in the proliferation and invasion of glioma through the PI3K/AKT/JAK2/STAT3 pathway [54]. IL-10 may contribute to glioma progression by suppressing the immune response [55]. The TLR4-specific blocking agent, TAK-242, confirmed that the effects of PSAP on glioma growth and the NF-kB signaling pathway are mediated through TLR4.

In summary, we found that secretory neurotrophic factor PSAP is overexpressed in glioma, and can bind to TLR4 to activate the Myd88-dependent NF-κB signaling pathway, which may induce the synthesis and secretion of inflammatory factors and promote the growth of
glial stem cells and tumor cells. Therefore, PSAP may be an important target for inhibiting glioma growth and improving glioma prognosis.

The following are the supplementary data related to this article.

**Funding sources**

This work was funded by National Natural Science Foundation of China (Nos. 81101917, 81207036, 81201802, 81673025), Program for Liaoning Excellent Talents in University (No. LR2014023), and Liaoning Province Natural Science Foundation (Nos. 20170541022, 20172250290). The funders did not play a role in manuscript design, data collection, data analysis, interpretation nor writing of the manuscript. Y.Z. and J.Z. contributed equally to this work. All authors read and approved the final version of the manuscript.

**Declarations of interests**

The authors have declared that no conflict of interest exists.

**Author contributions**

YZ and JZ conceived and designed the study; YJ and JZ performed the experiments and collected the data; PL, HG, YM and YSC performed Bioinformatics analysis and analyzed the data. YJ, JZ, LL and DZ interpreted results and wrote the manuscript. Y.Z. and J.Z. contributed equally to this work. All authors read and approved the final version of the manuscript.

**Acknowledgements**

We would like to acknowledge our lab colleagues for their support in the development of this article.

**References**

[1] Zhou D, Alver BM, Li S, Hladay RA, Thompson Jj, Schroeder MA, et al. Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 2018;19(1):43.

[2] Formolo CA, Williams R, Cordish-Dressman H, MacDonald Tj, Lee NH, Hatlout Y. Secretome signature of invasive glioblastoma multiforme. J Proteome Res 2011;10(7):3146-59.

[3] Fu MH, Wang CY, Hisieh Yt, Fang KM, Tzeng SF. Functional Role of Matrix gla Protein in Glioma Cell Migration. Mol Neurobiol 2018;55(6):4624–36.

[4] Augustin I, Goeldt V, Borgers A, Keri G, Voltell G, Radlwimmer B, et al. The Wnt secretion protein WntPv/Gpi17 promotes glioma tumorigenesis. EMBO Mol Med 2012;4(1):38–51.

[5] Joseph VC, Conroy S, Tomar T, Eoggens-Meijer E, Bhat K, Copey S, et al. TGF-beta is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis 2014;5:e1443.

[6] Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An overview of current molecular genetics. J Lipid Res 1992;33(9):1255–60.

[7] Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advari J, et al. Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics. Biochim Biophys Acta 2014;1846(10):1054–66.

[8] Meznaer MT, Kruger CL, Volk K, Biebbeck K, Cottrell GS, Heilemann M, et al. Biased signalling is an essential feature of TLR4 in glioma cells. Biochim Biophys Acta 2016;1863(12):3084–95.

[9] Moreno EM, Lavine D, Beutler B. Toll-like receptors. Current Biol 2011;21(13):R488–89.

[10] Deng S, Zhu S, Qiao Y, Liu YJ, Chen WH, Zhao G, et al. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell 2014;5(5):829–39.

[11] Huang JM, Zhang GN, Shi Y, Zha X, Zhi Y, Wang MM, et al. Atractylone-induced I-sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88/MD2-dependent pathways. Exp Cell Res 2014;338:175–84.

[12] Catsa P, Sirri S, Masiero B, Comi G, Bossi R, Ascoli G, et al. The role of TLR signaling in glioma cells. Brain Res 2014;1585:1–9.

[13] Ishihara S, Monik SM, Haga E. Mesenchymal stem cells in breast cancer: response to chemical and mechanical stimuli. Oncoscience 2017;4(1):128–34.

[14] Kooskhorup S, Lee TJ, Sun Y, Su S, Grabowski GA, Liu Z, et al. ABL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL. BMC Cancer 2018;18(1):509.

[15] Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, et al. Prosaposin-derived peptide alleviates ischaemia-induced hearing loss. Acta Otolaryngol 2013;133(5):462–8.

[16] Kooskhorup S, Lee TJ, Wang R, Sun Y, Delorme N, Hiraiwa M, et al. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP. J Cell Biochem 2007;101(3):631–41.

[17] Wu Y, Sun L, Zou X, Ju J, Liu H, Wang W, et al. Prosaposin, a regulator of estrogen receptor alpha, promotes breast cancer growth. Cancer Sci 2012;103(10):1820–5.

[18] Ali A, Cerevey L, Hao Y, McCartan D, O’Gara P, Hill A, et al. Prosaposin activates the angiogenesis receptor and potentiates resistance to endocrine treatment in breast cancer. Breast Cancer Res 2015;17:123.

[19] MehraPB,BarbhiyaMA,BhuniaS,SubbannayyaT,GowdaH,AdvariJ,et al. Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics. Biochim Biophys Acta 2014;1846(10):1054–66.

[20] Meznaer MT, Kruger CL, Volk K, Biebbeck K, Cottrell GS, Heilemann M, et al. Biased signalling is an essential feature of TLR4 in glioma cells. Biochim Biophys Acta 2016;1863(12):3084–95.

[21] Moreno EM, Lavine D, Beutler B. Toll-like receptors. Current Biol 2011;21(13):R488–89.

[22] Deng S, Zhu S, Qiao Y, Liu YJ, Chen WH, Zhao G, et al. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell 2014;5(5):829–39.

[23] Huang JM, Zhang GN, Shi Y, Zha X, Zhi Y, Wang MM, et al. Atractylone-induced I-sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88/MD2-dependent pathways. Exp Cell Res 2014;338:175–84.

[24] Catsa P, Sirri S, Masiero B, Comi G, Bossi R, Ascoli G, et al. The role of TLR signaling in glioma cells. Brain Res 2014;1585:1–9.

[25] Ishihara S, Monik SM, Haga E. Mesenchymal stem cells in breast cancer: response to chemical and mechanical stimuli. Oncoscience 2017;4(1):128–34.

[26] Kooskhorup S, Lee TJ, Sun Y, Su S, Grabowski GA, Liu Z, et al. ABL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL. BMC Cancer 2018;18(1):509.

[27] Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, et al. Prosaposin-derived peptide alleviates ischaemia-induced hearing loss. Acta Otolaryngol 2013;133(5):462–8.

[28] Kooskhorup S, Lee TJ, Wang R, Sun Y, Delorme N, Hiraiwa M, et al. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP. J Cell Biochem 2007;101(3):631–41.
of inflammatory responses in glioma. J Mol Med (Berlin, Germany) 2012;90(1):67–80.

[47] Yeung YT, McDonald KL, Crewal T, Munoz L. Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol 2013;168(3):591–606.

[48] Li G, Wang Z, Ye J, Zhang X, Wu H, Peng J, et al. Uncontrolled inflammation induced by AEG-1 promotes gastric cancer and poor prognosis. Cancer Res 2014;74(19):5541–52.

[49] Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011;102(1):35–41.

[50] Michelson N, Rincon-Torroella J, Quinones-Hinojosa A, Greenfield JP. Exploring the role of inflammation in the malignant transformation of low-grade gliomas. J Neuroimmunol 2016;297:132–40.

[51] Meini A, Sticozzi C, Massai L, Palmi M. A nitric oxide/ca(2+)/calmodulin/ERK1/2 mitogen-activated protein kinase pathway is involved in the mitogenic effect of IL-1beta in human astrocytoma cells. Br J Pharmacol 2008;153(8):1706–17.

[52] Paugh BS, Bryan L, Paugh SW, Wilczynska KM, Alvarez SM, Singh SK, et al. Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem 2009;284(6):3408–17.

[53] Giladi ND, Ziv-Av A, Lee HK, Finniss S, Cazacu S, Xiang C, et al. RTVP-1 promotes mesenchymal transformation of glialoma via a STAT-3/IL-6-dependent positive feedback loop. Oncotarget 2015;6(26):22680–97.

[54] de la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, et al. Dereglulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 2008;28(23):5870–8.

[55] Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 Produced by the Glioma Microenvironment is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer Res 2016;76(19):5671–82.